Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough?

Published:2017-04-26 Issue:2 Volume:71 Page:247-257
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Polónia António¹²^ORCID,Eloy Catarina¹²,Pinto João³,Braga Ana Costa⁴⁵,Oliveira Guilherme¹,Schmitt Fernando¹²⁶

Affiliation:

1. Department of Pathology; Ipatimup Diagnostics; Ipatimup; Porto Portugal

2. FMUP; Faculty of Medicine; University of Porto; Porto Portugal

3. Department of Pathology; Hospital Pedro Hispano; ULS Matosinhos; Matosinhos Portugal

4. Department of Pathology; Hospital Prof. Doutor Fernando Fonseca, EPE; Amadora Portugal

5. Nova Medical School; Faculdade de Ciências Médicas; Universidade Nova de Lisboa; Lisboa Portugal

6. Laboratoire national de santé; Dudelange Luxembourg

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/his.13208/fullpdf

Reference30 articles.

1. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial;Perez;J. Clin. Oncol.,2006

2. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis;Chen;Breast Cancer Res. Treat.,2012

3. The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice;Rakha;Histopathology,2014

4. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease;Cobleigh;J. Clin. Oncol.,1999

5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N. Engl. J. Med.,2001

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Image analysis for bright-field HER2 in situ hybridization: validation for clinical use;Virchows Archiv;2024-08-07

2. Artificial intelligence–assisted cancer diagnosis improves the efficiency of pathologists in prostatic biopsies;Virchows Archiv;2023-02-21

3. Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancer;Journal of Pathology Informatics;2022

4. HER2 in situ hybridization test in breast cancer: quantifying margins of error and genetic heterogeneity;Modern Pathology;2021-05-12

5. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?;Virchows Archiv;2019-04-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3